STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

AMRX AMNEAL PHARMACEUTICALS StockScouter® Report

2

StockScouter® Score

AMNEAL PHARMACEUTICALS, a small cap value company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is lower than the average for comparably-sized companies in the StockScouter universe. Positive

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • The multi-period measure of relative price change and consistency is well below average. Negative
  • The 50-day moving average for AMRX is significantly below its 200-day moving average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, value stocks will be in favor, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 100% done.
Progress: 20% done.
Low
High

Core Model Grades

F
N/A
C
F

Previous Ratings

3
4
5